The first-in-human dose escalation study utilized anti-B-cell maturation antigen, bispecific t-cell engager molecule AMG 420, to assess efficacy in patients with relapsed/refractory multiple myeloma. Results demonstrate a “high degree of clinical activity in patients with heavily pretreated multiple myeloma, irrespective of cytogenetic risk.”

“Both anti-BCMA BiTE and CAR-T have demonstrated promising efficacy results in patients with relapsed and/or refractory multiple myeloma. Multiple myeloma is a complex blood cancer that has historically been difficult to treat. Anti-BCMA therapies may provide another potentially effective option in a category with high unmet need.” – Alex Minella, MD

To read the full article, visit MedPage Today. The study can be found in the Journal of Clinical Oncology.

Tags: bispecific t cell engagers, BCMA, patient care, bite